Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia
- 10 August 2012
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (23) , 2820-2822
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- The clinically active BTK inhibitor PCI-32765 targets B-cell receptor– and chemokine-controlled adhesion and migration in chronic lymphocytic leukemiaBlood, 2012
- Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaClinical Cancer Research, 2011
- The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulationCancer, 2010
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemiaBlood, 2010
- Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase–dependent pathwayBlood, 2010
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II StudyJournal of Clinical Oncology, 2006
- Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular LymphomaJournal of Clinical Oncology, 2005
- Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working groupAmerican Journal of Hematology, 1988